In addition, new NAMPT inhibitors have been conjugated with antibodies, which are called ADCs (antibody–drug conjugates), with the aim of specifically targeting the drug to the tumour while avoiding damage to healthy tissues. The gene discussed is NAMPT; the disease is neoplasm.